ストックスクリーナーアプリを入手
11.89
1.74%
-0.21
アフターアワーズ：
12.54
0.65
+5.47%
前日終値:
$12.10
開ける：
$12.04
24時間の取引高:
35,389
Relative Volume:
0.35
時価総額：
$316.05M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.45%
1か月 パフォーマンス:
-17.89%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.76
$12.04
1週間の範囲:
$11.76
$13.00
52週間の値動き範囲:
$11.76
$16.20
Carlsmed Inc Stock (CARL) Company Profile
CARL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
11.89 | 321.63M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
291.21 | 48.40B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
72.09 | 14.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
62.58 | 11.99B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
92.74 | 8.13B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.80 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-18 | 開始されました | BTIG Research | Buy |
| 2025-08-18 | 開始されました | BofA Securities | Buy |
| 2025-08-18 | 開始されました | Goldman | Buy |
| 2025-08-18 | 開始されました | Piper Sandler | Overweight |
| 2025-08-18 | 開始されました | Truist | Buy |
Carlsmed Inc (CARL) 最新ニュース
Earnings call transcript: Carlsmed Q3 2025 sees 98% revenue growth - Investing.com
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance - Ortho Spine News
Carlsmed Secures $60 Million Credit Facility Amendment - MSN
Carlsmed, Inc. (CARL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Carlsmed, Inc. (NASDAQ:CARL) Sees Significant Decrease in Short Interest - MarketBeat
Carlsmed, Inc. (CARL) Stock Price, News, Quote & History - Yahoo! Finance Canada
carlsmed, inc. Earnings dates - RTTNews
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | User | thepilotnews.com - FinancialContent
Carlsmed, Inc.Common Stock (Nasdaq:CARL) Stock Quote - FinancialContent
Carlsmed, Inc. (NASDAQ:CARL) Short Interest Update - MarketBeat
ETFs Investing in Carlsmed, Inc. Stocks - TradingView
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - MSN
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
Carlsmed, Inc.(NasdaqGS: CARL) added to Russell 3000E Growth Benchmark - MarketScreener
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed Inc (CARL) 財務データ
Carlsmed Inc (CARL) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.59%
大文字化:
|
ボリューム (24 時間):